[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-oric-pharmaceuticals-sinks-22-as-jj-presents-rival-prostate-cancer-data-EN":222},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218],{"slug":151,"title":152,"modified":153},"bloomberg","Bloomberg","2025-01-16T14:23:44",{"slug":155,"title":156,"modified":157},"morningstar","Morningstar","2025-01-16T14:25:16",{"slug":159,"title":160,"modified":161},"sentieo","Sentieo","2025-01-16T17:58:27",{"slug":163,"title":164,"modified":165},"googlefinance","Google Finance","2025-01-17T19:39:37",{"slug":167,"title":168,"modified":169},"tradingview","TradingView","2025-01-16T18:17:01",{"slug":171,"title":172,"modified":173},"factset","Factset","2025-01-16T18:20:16",{"slug":175,"title":176,"modified":177},"finviz","Finviz","2025-01-16T18:23:40",{"slug":179,"title":180,"modified":181},"ycharts","YCharts","2025-01-16T18:32:19",{"slug":183,"title":184,"modified":185},"marketbeat","MarketBeat","2025-03-11T00:27:23",{"slug":187,"title":188,"modified":189},"benzinga","Benzinga","2025-03-11T00:31:00",{"slug":191,"title":192,"modified":193},"gurufocus","Gurufocus","2025-03-11T00:31:12",{"slug":195,"title":196,"modified":197},"fast-graphs","FAST Graphs","2025-03-11T00:31:19",{"slug":199,"title":200,"modified":201},"tipranks","TipRanks","2025-03-11T00:31:26",{"slug":203,"title":204,"modified":205},"seeking-alpha","Seeking Alpha","2025-03-11T00:31:45",{"slug":207,"title":208,"modified":209},"thestreet","TheStreet","2025-03-11T00:31:52",{"slug":211,"title":212,"modified":213},"investing-com","Investing.com","2025-03-11T00:32:00",{"slug":215,"title":216,"modified":217},"zacks","Zacks","2025-03-26T15:40:40",{"slug":219,"title":220,"modified":221},"alphasense","AlphaSense","2025-03-11T00:32:15",{"post":223,"seo":259,"relatedPosts":266,"suggestedPosts":345},{"id":224,"title":225,"date":226,"modified":227,"excerpt":228,"content":229,"wordCount":230,"lang":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":239,"editor":245,"categories":250,"relatedPosts":256,"seo":257},145819,"ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data","2026-10-26T16:39:42","2026-10-26T16:39:48","\u003Cp>Friday’s good news didn’t last long\u003C\u002Fp>\n","\n\u003Ch2 id=\"h-key-takeaways\" class=\"wp-block-heading\">Key Takeaways\u003C\u002Fh2>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>ORIC Pharmaceuticals shares fell 22% today after Johnson & Johnson presented early data for JNJ-6143, a rival prostate cancer drug.\u003C\u002Fli>\n\n\n\n\u003Cli>The drop looks too big, since J&J’s data comes from a small early-stage study and ORIC’s own prostate cancer drug is already in a Phase 3 trial.\u003C\u002Fli>\n\n\n\n\u003Cli>At the 50 mg dose, J&J’s drug produced a 75% response rate in 16 patients with measurable disease, and those patients had already been through a median of four treatments.\u003C\u002Fli>\n\n\n\n\u003Cli>ORIC has $388 million in cash and investments and expects it to last into the second half of 2028, past the main readout from its Phase 3.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>ORIC Pharmaceuticals (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=303713108&tid=656973915\">ORIC\u003C\u002Fa>)\u003C\u002Fstrong> is down 22% today, and the bad news isn’t even its own. Over the weekend, \u003Cstrong>Johnson & Johnson (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=139677&tid=2623227\">JNJ\u003C\u002Fa>)\u003C\u002Fstrong> presented early data on its experimental prostate cancer drug, JNJ-6143. Investors read it as a direct threat to ORIC’s lead drug, rinzimetostat.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-j-amp-j-s-immaculate-numbers\" class=\"wp-block-heading\">J&J’s “immaculate” numbers\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">At the ESMO Congress on Saturday, J&J \u003Ca href=\"https:\u002F\u002Fwww.morningstar.com\u002Fnews\u002Fpr-newswire\u002F20261025ny80315\u002Fjohnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-cancer-with-jnj-6143-a-first-in-class-riptac-molecule\">reported Phase 1 results\u003C\u002Fa> in men with advanced prostate cancer who’d had a median of four prior treatments. At the 50 mg dose, 75% of patients with measurable disease (12 of 16) had a confirmed complete or partial response. And 77% of 38 patients saw their PSA fall by at least half.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Leerink analyst Asthika Goonewardene called the data “immaculate” and said the results “dial up the potential threat level” for rinzimetostat.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>TIKR tracks 15 analysts on ORIC Pharmaceuticals. How many say “Buy”?\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">See the full breakdown of Buy, Hold, and Sell ratings on ORIC Pharmaceuticals, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. \u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fvaluation-model-builder?ref=tikrblog\">See ORIC Pharmaceuticals’ Analyst Ratings\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-a-lot-rides-on-rinzimetostat\" class=\"wp-block-heading\">A lot rides on rinzimetostat\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Rinzimetostat is ORIC’s most advanced drug. In July, ORIC \u003Ca href=\"https:\u002F\u002Fwww.biospace.com\u002Fpress-releases\u002Foric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with-bayer\">started Himalayas-1\u003C\u002Fa>. It’s a Phase 3 trial pairing rinzimetostat with Bayer’s darolutamide in men whose prostate cancer has spread and kept growing after abiraterone, a standard hormone treatment.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">J&J’s patients had been through more treatment. But if JNJ-6143 holds up, I’d expect J&J to push it into earlier patients, right where rinzimetostat is headed.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">ORIC had $265 million of cash and short-term investments at June 30…\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3024\" height=\"2016\" data-public-id=\"images\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3024,h_2016,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA\" alt=\"Bar chart from TIKR of ORIC Pharmaceuticals' cash and short-term investments, $ millions, last 8 quarters (to June 30, 2026).\" class=\"wp-post-145819 wp-image-145817\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1793030374\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 3024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 300w\" sizes=\"auto, (max-width: 3024px) 100vw, 3024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">ORIC Pharmaceuticals (ORIC): cash and short-term investments, $ millions, last 8 quarters (to June 30, 2026) (\u003Cstrong>TIKR\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">…plus $123 million in long-term investments, or $388 million in all. \u003Ca href=\"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F0001796280\u002F000119312526330568\u002Foric-ex99_1.htm\">Management expects\u003C\u002Fa> that to last into the second half of 2028, past Himalayas-1’s main readout.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">At a market value of about $1.1 billion, that still leaves roughly $700 million on the pipeline, and rinzimetostat is the biggest piece of it.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-the-lung-drug-is-still-there\" class=\"wp-block-heading\">The lung drug is still there\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">On Friday, ORIC \u003Ca href=\"https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F10\u002F23\u002F3387076\u002F0\u002Fen\u002Foric-pharmaceuticals-presents-potential-best-in-class-data-for-enozertinib-in-1l-nsclc-patients-with-egfr-atypical-mutations-at-esmo-congress-2026-and-plans-to-advance-enozertinib-.html\">reported an 84% confirmed response rate\u003C\u002Fa> for enozertinib, its lung cancer drug, in 26 untreated patients. It plans to start a Phase 3 trial in the first half of 2027. This morning, Stifel raised its target to $18 from $14.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Analysts’ consensus target has climbed over the past year…\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3024\" height=\"2016\" data-public-id=\"images\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3024,h_2016,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA\" alt=\"Line chart from TIKR of ORIC Pharmaceuticals' analysts' consensus (mean) price target, $ per share, last year.\" class=\"wp-post-145819 wp-image-145818\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1793030372\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 3024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 300w\" sizes=\"auto, (max-width: 3024px) 100vw, 3024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">ORIC Pharmaceuticals (ORIC): analysts’ consensus (mean) price target, $ per share, last year (\u003Cstrong>TIKR\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">…to about $22, more than double where the stock trades now.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">My take: J&J’s data is a real threat, but it comes from 16 patients in a Phase 1 study. ORIC has a Phase 3 underway, a second drug heading into one, and the cash to reach the readout. Losing [22%] on a rival’s early study looks like too much to me.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Of course, ORIC still owes investors a rinzimetostat update this year. If that update looks weaker next to J&J’s numbers, the selloff will look a lot more reasonable.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-so-what-is-oric-pharmaceuticals-stock-actually-worth\" class=\"wp-block-heading\">So what is ORIC Pharmaceuticals stock actually worth?\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what ORIC Pharmaceuticals could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fvaluation-model-builder?ref=tikrblog\">Value ORIC Pharmaceuticals for free\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch3 id=\"h-disclaimer\" class=\"wp-block-heading\">\u003Cstrong>Disclaimer:\u003C\u002Fstrong>\u003C\u002Fh3>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cem>Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!\u003C\u002Fem>\u003C\u002Fp>\n",746,"en","\u002Fblog\u002Foric-pharmaceuticals-sinks-22-as-jj-presents-rival-prostate-cancer-data","oric-pharmaceuticals-sinks-22-as-jj-presents-rival-prostate-cancer-data","images\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793030373\u002Fimages\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d.png?_i=AA",{"altText":237,"imageCredit":238},"ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data","MangoStar_Studio from Getty Images via Canva",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":244},"Roxanna Maglangit","roxtikr","author","",[],{"name":246,"slug":247,"role":248,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":249},"Michael Douglass","MichaelDouglass","editor",[],[251],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},"General Investing","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",0,[],{"title":237,"metaDesc":258,"opengraphDescription":258,"twitterTitle":237,"twitterDescription":258},"Friday’s good news didn’t last long",{"title":225,"description":260,"twitterTitle":225,"twitterDescription":260,"author":240,"articlePublisher":261,"articlePublishedTime":226,"articleModifiedTime":227,"twitterLabel1":262,"twitterData1":263,"ogTitle":225,"ogDescription":260,"ogUrl":232,"ogImage":235,"ogImageWidth":264,"ogImageHeight":265,"ogImageSecureUrl":235,"ogImageAlt":237,"twitterImage":235},"Friday’s good news didn’t last long","TIKR.com","Est. reading time","5 minutes",1200,630,[267,283,298,315,330],{"id":255,"title":268,"date":269,"excerpt":270,"wordCount":271,"uri":272,"slug":273,"cloudinaryAssetId":274,"featuredImageOriginalUrl":275,"featuredImageMetadata":276,"author":277,"categories":280,"relatedPosts":282},"Tesla Soars 6% on Barclays Upgrade Calling SpaceX Merger \"Key Part of the Tesla Bull Case\"","2026-10-26 16:28:00","A takeover floor is only as good as the vote behind it",716,"\u002Fblog\u002Ftesla-soars-6-on-barclays-upgrade-calling-spacex-merger-key-part-of-the-tesla-bull-case","tesla-soars-6-on-barclays-upgrade-calling-spacex-merger-key-part-of-the-tesla-bull-case","images\u002Felon-musk-onstage-spacex-falcon-9-launch\u002Felon-musk-onstage-spacex-falcon-9-launch","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793023734\u002Fimages\u002Felon-musk-onstage-spacex-falcon-9-launch\u002Felon-musk-onstage-spacex-falcon-9-launch.png?_i=AA",{"altText":268},{"name":246,"slug":278,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":279},"michaeldouglass",[],[281],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":284,"date":285,"excerpt":286,"wordCount":287,"uri":288,"slug":289,"cloudinaryAssetId":290,"featuredImageOriginalUrl":291,"featuredImageMetadata":292,"author":293,"categories":295,"relatedPosts":297},"Wall Street Expects Tesla to Burn $4 Billion This Quarter. A Year Ago It Generated $4 Billion.","2026-10-26 16:21:00","Tonight's cash number shows who's paying for the robots",861,"\u002Fblog\u002Fwall-street-expects-tesla-to-burn-4-billion-this-quarter-a-year-ago-it-generated-4-billion","wall-street-expects-tesla-to-burn-4-billion-this-quarter-a-year-ago-it-generated-4-billion","images\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792699327\u002Fimages\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva.png?_i=AA",{"altText":284},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":294},[],[296],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":299,"date":300,"excerpt":301,"wordCount":302,"uri":303,"slug":304,"cloudinaryAssetId":305,"featuredImageOriginalUrl":306,"featuredImageMetadata":307,"author":308,"categories":312,"relatedPosts":314},"Intel Gains 4% on New Street Upgrade as Server CPU Crunch Is Set to \"Persist for Years\"","2026-10-26 16:01:15","A bold call, three days before Intel's big test",701,"\u002Fblog\u002Fintel-gains-4-on-new-street-upgrade-as-server-cpu-crunch-is-set-to-persist-for-years","intel-gains-4-on-new-street-upgrade-as-server-cpu-crunch-is-set-to-persist-for-years","images\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792699318\u002Fimages\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva.png?_i=AA",{"altText":299},{"name":309,"slug":310,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":311},"David Hanson","davidtikr",[],[313],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":316,"date":317,"excerpt":318,"wordCount":319,"uri":320,"slug":321,"cloudinaryAssetId":305,"featuredImageOriginalUrl":306,"featuredImageMetadata":322,"author":323,"categories":327,"relatedPosts":329},"Bill Gates: Meta's Muse Is \"the First Truly Great Consumer AI Product\"","2026-10-26 15:52:36","High praise, and now the clock is ticking",1067,"\u002Fblog\u002Fbill-gates-metas-muse-is-the-first-truly-great-consumer-ai-product","bill-gates-metas-muse-is-the-first-truly-great-consumer-ai-product",{"altText":316},{"name":324,"slug":325,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":326},"Bobby Sankhagowit","bobby",[],[328],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":331,"date":332,"excerpt":333,"wordCount":334,"uri":335,"slug":336,"cloudinaryAssetId":337,"featuredImageOriginalUrl":338,"featuredImageMetadata":339,"author":340,"categories":342,"relatedPosts":344},"Nvidia Could Exploit \"Completely Legal\" China Loophole Worth Billions. But It (Probably) Won't.","2026-10-26 15:50:14","It's got better things to do with its chips.",988,"\u002Fblog\u002Fnvidia-could-exploit-completely-legal-china-loophole-worth-billions-but-it-probably-wont","nvidia-could-exploit-completely-legal-china-loophole-worth-billions-but-it-probably-wont","images\u002Fdoubtful-man-with-glasses-in-hand-data-center\u002Fdoubtful-man-with-glasses-in-hand-data-center","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793027299\u002Fimages\u002Fdoubtful-man-with-glasses-in-hand-data-center\u002Fdoubtful-man-with-glasses-in-hand-data-center.png?_i=AA",{"altText":331},{"name":246,"slug":278,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":341},[],[343],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],[346,366,381,395,410,430,445,460,475],{"id":255,"title":347,"date":348,"excerpt":349,"wordCount":350,"uri":351,"slug":352,"cloudinaryAssetId":353,"featuredImageOriginalUrl":354,"featuredImageMetadata":355,"author":356,"categories":360,"relatedPosts":365},"Up 13% In Last 12 Months, Can Arista Networks Stock Give Better Returns in 2026?","2026-10-26 12:57:00","Arista stock is up 10% in a year. See what TIKR’s Valuation Model says about ANET’s upside, with a $275 price target by December 2028.",1099,"\u002Fblog\u002Farista-networks-stock-valuation-anet-2026","arista-networks-stock-valuation-anet-2026","images\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793010558\u002Fimages\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva.png?_i=AA",{"altText":347},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":359},"Aditya Raghunath","adityatikr",[],[361],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},"Valuation","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":255,"title":367,"date":368,"excerpt":369,"wordCount":370,"uri":371,"slug":372,"cloudinaryAssetId":373,"featuredImageOriginalUrl":374,"featuredImageMetadata":375,"author":376,"categories":378,"relatedPosts":380},"Down 48% In Last 12 Months, Can SoFi Stock Give Better Results in 2026?","2026-10-26 12:45:00","SoFi stock is down 51% in a year. See what TIKR’s Valuation Model says about SOFI’s upside, with a $22 price target by December 2028.",1081,"\u002Fblog\u002Fsofi-stock-valuation-sofi-2026","sofi-stock-valuation-sofi-2026","images\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793015325\u002Fimages\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva.png?_i=AA",{"altText":367},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":377},[],[379],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},[],{"id":255,"title":382,"date":368,"excerpt":383,"wordCount":384,"uri":385,"slug":386,"cloudinaryAssetId":387,"featuredImageOriginalUrl":388,"featuredImageMetadata":389,"author":390,"categories":392,"relatedPosts":394},"Up Just 9% in the Last 12 Months, Can Palantir Stock Give Better Returns in 2026?","Palantir stock is up just 4% in a year. See what TIKR’s Valuation Model says about PLTR’s upside, with a $529 target by December 2028.",1024,"\u002Fblog\u002Fpalantir-stock-valuation-pltr-2026","palantir-stock-valuation-pltr-2026","images\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793003212\u002Fimages\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c.png?_i=AA",{"altText":382},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":391},[],[393],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},[],{"id":255,"title":396,"date":397,"excerpt":398,"wordCount":399,"uri":400,"slug":401,"cloudinaryAssetId":402,"featuredImageOriginalUrl":403,"featuredImageMetadata":404,"author":405,"categories":407,"relatedPosts":409},"Down 56% In Last 12 Months, Can AppLovin Stock Give Better Returns in 2026?","2026-10-26 12:33:00","AppLovin stock is down 60% in a year. See what TIKR’s Valuation Model says about APP’s upside, with a $366 price target by December 2028.",1139,"\u002Fblog\u002Fapplovin-stock-valuation-app-2026","applovin-stock-valuation-app-2026","images\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793013215\u002Fimages\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2.png?_i=AA",{"altText":396},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":406},[],[408],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},[],{"id":255,"title":411,"date":412,"excerpt":413,"wordCount":414,"uri":415,"slug":416,"cloudinaryAssetId":417,"featuredImageOriginalUrl":418,"featuredImageMetadata":419,"author":420,"categories":424,"relatedPosts":429},"ExxonMobil Stock Hit a Record Close as Brent Topped $116. Here’s Where the Stock Could Go by 2030","2026-10-26 07:55:00","ExxonMobil closed at a record $183.21 on October 23 as Brent topped $116, and now trades above the Street’s mean target. Its CFO says Pioneer synergies doubled and Exxon aims to double Permian recovery with fewer wells, a cost lever the company controls.",791,"\u002Fblog\u002Fexxonmobil-stock-hit-a-record-close-as-brent-topped-116-heres-where-the-stock-could-go-by-2030","exxonmobil-stock-hit-a-record-close-as-brent-topped-116-heres-where-the-stock-could-go-by-2030","images\u002F13-10\u002F13-10","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976181\u002Fimages\u002F13-10\u002F13-10.png?_i=AA",{"altText":411},{"name":421,"slug":422,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":423},"Wiltone Asuncion","wiltonetikr",[],[425],{"name":426,"slug":427,"uri":428,"description":243,"postsCount":255},"Stock Reviews","reviews","\u002Fblog\u002Fcategory\u002Freviews",[],{"id":255,"title":431,"date":432,"excerpt":433,"wordCount":434,"uri":435,"slug":436,"cloudinaryAssetId":437,"featuredImageOriginalUrl":438,"featuredImageMetadata":439,"author":440,"categories":442,"relatedPosts":444},"Rivian Hit a 52-Week Low the Day After Buying an AI Simulation Startup. Here’s What October 29 Has to Show","2026-10-26 07:50:00","Rivian touched a 52-week low the day after buying an AI simulation startup, extending a 19% slide that began weeks earlier. The October 29 report now has to show the cost line can carry the autonomy spending.",925,"\u002Fblog\u002Frivian-hit-a-52-week-low-the-day-after-buying-an-ai-simulation-startup-heres-what-october-29-has-to-show","rivian-hit-a-52-week-low-the-day-after-buying-an-ai-simulation-startup-heres-what-october-29-has-to-show","images\u002F12-10_145310df477\u002F12-10_145310df477","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976166\u002Fimages\u002F12-10_145310df477\u002F12-10_145310df477.png?_i=AA",{"altText":431},{"name":421,"slug":422,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":441},[],[443],{"name":426,"slug":427,"uri":428,"description":243,"postsCount":255},[],{"id":255,"title":446,"date":447,"excerpt":448,"wordCount":449,"uri":450,"slug":451,"cloudinaryAssetId":452,"featuredImageOriginalUrl":453,"featuredImageMetadata":454,"author":455,"categories":457,"relatedPosts":459},"Robinhood Stock Fell 15% in October Before Its Q3 Report. Here’s Where It Could Go by 2030","2026-10-26 07:45:00","Robinhood fell 6.73% in two sessions, in step with Coinbase, before its October 27 report. Two October 22 developments point to crypto activity that may not show up in its crypto revenue line: bitcoin price contracts and Morpho’s first lending markets for its stock tokens.",854,"\u002Fblog\u002Frobinhood-stock-fell-15-in-october-before-its-q3-report-heres-where-it-could-go-by-2030","robinhood-stock-fell-15-in-october-before-its-q3-report-heres-where-it-could-go-by-2030","images\u002F11-11_145309e717b\u002F11-11_145309e717b","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976143\u002Fimages\u002F11-11_145309e717b\u002F11-11_145309e717b.png?_i=AA",{"altText":446},{"name":421,"slug":422,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":456},[],[458],{"name":426,"slug":427,"uri":428,"description":243,"postsCount":255},[],{"id":255,"title":461,"date":462,"excerpt":463,"wordCount":464,"uri":465,"slug":466,"cloudinaryAssetId":467,"featuredImageOriginalUrl":468,"featuredImageMetadata":469,"author":470,"categories":472,"relatedPosts":474},"Walmart Stock Rose 15% in October Without a Higher Earnings Forecast. Here’s Where It Could Go by 2031","2026-10-26 07:40:00","Walmart rose 15.4% from September 30 to October 23, yet analysts’ next-12-months EPS estimate stayed at $3.00 a share. Almost all of the gain came from a higher multiple, ahead of a November 19 report guided to 0% to 3% EPS growth.",832,"\u002Fblog\u002Fwalmart-stock-rose-15-in-october-without-a-higher-earnings-forecast-heres-where-it-could-go-by-2031","walmart-stock-rose-15-in-october-without-a-higher-earnings-forecast-heres-where-it-could-go-by-2031","images\u002F10-14_145308a5c00\u002F10-14_145308a5c00","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976123\u002Fimages\u002F10-14_145308a5c00\u002F10-14_145308a5c00.png?_i=AA",{"altText":461},{"name":421,"slug":422,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":471},[],[473],{"name":426,"slug":427,"uri":428,"description":243,"postsCount":255},[],{"id":255,"title":476,"date":477,"excerpt":478,"wordCount":479,"uri":480,"slug":481,"cloudinaryAssetId":482,"featuredImageOriginalUrl":483,"featuredImageMetadata":484,"author":485,"categories":487,"relatedPosts":489},"Apple Briefly Topped Nvidia as Nvidia’s Slide Reached 12%. Here’s Where Apple Stock Could Go by 2030","2026-10-26 07:35:00","Apple briefly passed Nvidia as the world’s most valuable company on October 23, hitting a record $351.73. Its AI strategy needs little capex, but at 38 times earnings, the November 2 margin print carries the multiple.",845,"\u002Fblog\u002Fapple-briefly-topped-nvidia-as-nvidias-slide-reached-12-heres-where-apple-stock-could-go-by-2030","apple-briefly-topped-nvidia-as-nvidias-slide-reached-12-heres-where-apple-stock-could-go-by-2030","images\u002F9-15_1453077213e\u002F9-15_1453077213e","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976106\u002Fimages\u002F9-15_1453077213e\u002F9-15_1453077213e.png?_i=AA",{"altText":476},{"name":421,"slug":422,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":486},[],[488],{"name":426,"slug":427,"uri":428,"description":243,"postsCount":255},[]]